Targeted Therapies

DIPG therapy selection is framed around tumor biology rather than only clinical presentation. Cytotoxic agents were the most frequently included, registered, and locally produced subclass of anticancer medicines. The supplied text does not specify the particular biomarkers, therapies, or decision thresholds used in the framework. Headline registration numbers can obscure poor access to newer cancer therapies because older cytotoxic medicines dominate registration patterns. Targeted therapy selection is influenced by tumor tissue assessment and biomarker profiling. Targeted therapies were poorly represented in national lists and remained a major access gap. High medicine costs and limited public budgets discouraged countries from listing high-cost and innovative agents. The article describes a framework for targeted therapy selection in H3K27-altered DIPGs.